Clinical Context
Melanoma is a type of skin cancer that arises from melanocytes and can be aggressive, leading to significant morbidity and mortality. In the United States, melanoma accounts for about 1% of all skin cancers but causes the majority of skin cancer deaths. Current treatment options for high-risk melanoma include surgical resection and adjuvant therapies such as immune checkpoint inhibitors. However, many patients experience recurrence after initial treatment, indicating a need for more effective adjuvant therapies. The KEYNOTE-942 trial evaluates the combination of pembrolizumab and mRNA-4157, an individualized neoantigen therapy, to address this gap in treatment efficacy.
Q: What is pembrolizumab (Keytruda) approved for?
A: Pembrolizumab is approved for the treatment of melanoma, particularly in patients with unresectable or metastatic disease. The FDA has also approved it for adjuvant treatment in high-risk melanoma following surgical resection based on clinical trial data showing improved outcomes.
Q: How does pembrolizumab work?
A: Pembrolizumab is an immune checkpoint inhibitor that blocks the PD-1 receptor on T cells, enhancing the immune response against cancer cells. It is part of a class of therapies that help the immune system recognize and attack tumors, differing from traditional chemotherapies that directly kill cancer cells.
Q: What is the recommended dose of pembrolizumab?
A: Pembrolizumab is administered at a dose of 200 mg via intravenous infusion every 3 weeks. Clinicians should consult current prescribing information for full dosing guidance. Full dosing guidance is available in the prescribing information for pembrolizumab (Keytruda). Clinicians should consult the current label before prescribing.
Q: What are the most common side effects of pembrolizumab?
A: Common side effects of pembrolizumab include fatigue, rash, pruritus, diarrhea, and immune-mediated reactions. Specific frequencies are not available in the public source summary, and clinicians are advised to refer to the prescribing information for a complete list of adverse events.